NIH-funded research Career grant

Blocking a protein to reduce allergic responses in children

Official title: Inhibiting CD4+ Th2 development and function by CFTR activity

Funded at University of Iowa · NIH-11042218 · Data updated 2026-11-12

This study is looking at how a protein called CFTR affects the immune system in kids with asthma and allergies, hoping to find new ways to help them avoid bad allergic reactions.

Quick facts

Grant typeCareer grant
Study typeNIH-funded research
Funding institutionUniversity of Iowa
NIH-funded
Lab location1 site (Iowa City, United States)
Project startFebruary 22, 2024
Project endJanuary 31, 2029
Funding year2025
Award (this year)$188,676
NIH project number5K08AI181763-03
Project IDNIH-11042218 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are children aged 0-11 years who suffer from asthma or other allergic diseases.

Less likely to help

Patients who do not have allergic diseases or are older than 11 years may not benefit from this research.

What this research studies

This research investigates how the cystic fibrosis transmembrane conductance regulator (CFTR) protein affects the immune response in children with allergic diseases, particularly asthma. By studying how CFTR influences the development of specific immune cells called CD4+ T cells, the researchers aim to understand how to reduce harmful allergic reactions. The study uses animal models to explore the relationship between CFTR activity and allergic inflammation, focusing on the role of CFTR in regulating T helper 2 (Th2) cell responses. If successful, this research could lead to new treatments that help manage or prevent severe allergic reactions in young patients.

Why it matters

Potential benefit: If successful, this research could provide new therapeutic strategies to reduce allergic inflammation and improve the quality of life for children suffering from asthma and related allergic conditions.

How similar studies have gone: Previous research has shown that targeting immune responses can effectively reduce allergic reactions, suggesting that this approach may also yield positive results.

Where this research is happening

  • University of Iowa
    Iowa City, United States
    Active

Researchers

  • Principal investigator: Cook, Daniel Paul — University of Iowa
  • Study coordinator: Cook, Daniel Paul

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.